INTRODUCTION {#sec1-1}
============

About 15% of couples do not achieve pregnancy within 1 year and seek medical treatment for infertility. In infertile couples, male factor infertility contributes to 50% of cases.[@ref1][@ref2] Primary hypogonadism is characterized by impaired testicular function, which may affect spermatogenesis and/or testosterone synthesis. Oligozoospermic and azoospermic men (i.e., due to nonobstructive spermatogenic dysfunction) have been found to be hypogonadal in approximately 43%--45% of cases.[@ref3][@ref4]

Estradiol (E~2~) plays an important role in several functions of gonadal axis regulation and spermatogenesis. In men, most bioavailable E~2~ is primarily created through peripheral aromatization of circulating testosterone (T) in adipose tissue. Several studies have described treatments which block E~2~-mediated negative feedback on the hypothalamic--pituitary axis (HPA), which, in turn, may lead to increases in luteinizing/follicle-stimulating hormone (LH/FSH) secretion and T production.[@ref5][@ref6][@ref7]

Aromatase inhibitors (AIs) are well established for the treatment of metastatic breast cancer, and their use has also been adapted to the treatment of hypogonadal men by altering the T/E~2~ ratio.[@ref8][@ref9][@ref10][@ref11] Multiple AIs have been used in off-label trials in the literature, but the most commonly tested steroidal AI has been testolactone, and the most commonly tested nonsteroidal AIs have been anastrozole and letrozole.[@ref12]

There is no consensus in the literature regarding the role of AIs in the medical management of hypogonadal oligo-azoospermic males, although multiple studies have examined these medications for this purpose.[@ref13] The aim of the present systematic review and meta-analysis was to critically evaluate the literature for the effects of AIs on the treatment of hypogonadism and infertility through assessment of hormonal profile, semen parameters, and drug tolerability.

MATERIALS AND METHODS {#sec1-2}
=====================

Our goal was to examine the current evidence of the use of AIs in the medical management of hypoandrogenic males and to evaluate the results of trials reporting the available off-label use of AIs (*e.g*., testolactone, letrozole, and anastrozole) as a treatment for male infertility. In particular, we analyzed the impact of AIs in T and T/E~2~ ratio modification, impact of AIs on semen parameters, drug tolerability, and side effects.

 {#sec2-1}

### Evidence acquisition {#sec3-1}

We performed a systematic search in PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to December 2018, without language restriction, to identify clinical trials implementing the use of AIs as a treatment for male infertility and reporting the clinical outcomes on serum hormones and/or semen parameters. The feature of related articles in PubMed was used to identify further papers. The reference lists of the studies included were also screened. Only original articles were included and critically evaluated. We excluded case reports as well as abstracts and reports from meetings. An expert librarian was involved in the design of the search strategy and in the conduct of the literature search. Accordingly, we searched publications using the following primary and secondary fields: "male infertility" and "aromatase inhibitors" and "hypogonadism" and "oligozoospermia" and "cryptozoospermia" and "azoospermia" and "serum testosterone and/or estradiol" and "sperm concentration and total sperm count" (primary fields); "testosterone to estradiol ratio" and "Testolactone" or "Letrozole" or "Anastrozole" and "side effects" and "nonrandomized and randomized trials" (secondary fields). All search terms included in the present review are summarized in **[Supplementary Table 1](#T1){ref-type="table"}**. For all studies, we evaluated the level of evidence (LE) according to the European Association of Urology (EAU) guidelines (**[Table 1](#T2){ref-type="table"}**).[@ref14]

###### 

Research terms analysis (primary and secondary fields)

  Key words -- primary fields   Key words -- secondary fields
  ----------------------------- -----------------------------------
  Male infertility              Testosterone to estradiol ratio
  Aromatase inhibitors          Testolactone
  Hypogonadism                  Anastrozole
  oligozoospermia               Letrozole
  Cryptozoospermia              Aromatase inhibitors side effects
  Azoospermia                   Bone metabolism
  Serum testosterone            Osteoarticular side effects
  Serum estradiol               Klinefelter's syndrome
  Sperm concentration           Obesity
  Total sperm count             Randomized clinical trial
  Sperm morphology              Nonrandomized clinical trial
  Sperm motility                

###### 

Characteristics of the trials analyzed

  Study, year, country                      Study design                                                                          Treatment enclosed                                      Sample size (n)                                              Age (year), median (range); mean±s.d.   Infertility etiology, n (%)                                                                                                                                                                                                                                                                                            Follow-up (month)   LE
  ----------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------ --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----
  Clark and Sherins[@ref19] 1989, USA       Prospective, randomized, double-blind, placebo-controlled crossover (single center)   Testolactone 2 g daily Placebo                          Total: 25                                                    NR                                      Idiopathic                                                                                                                                                                                                                                                                                                             Baseline, 8, 16     1b
  Pavlovich *et al*.[@ref21] 2001, USA      Prospective, nonrandomized, case--control (single center)                             Testolactone 100--200 mg daily                          Total: 104 Testolactone (*n*=74) Control (*n*=40)            37 (31--43) 40 (37--40)                 Idiopathic: 12 (26.6), Klinefelter's syndrome: 6 (13.3), Chromosome Y microdeletion: 5 (11.1), cryptorchidism: 5 (11.5), varicocele: 14 (21.1)                                                                                                                                                                         Baseline, 3         2a
  Raman and Schlegel[@ref22] 2002, USA      Prospective, nonrandomized, case--control (single center)                             Testolactone 100--200 mg daily Anastrozole 1 mg daily   Total: 140 Testolactone (*n*=74) Anastrozole (*n*=101)       NR                                      Testolactone (*n*=74): Klinefelter's syndrome: 17 (22.9), varicocele repair: 18 (24.3), varicocele present: 12 (16.2), overweight (BMI \>35 kg m^−2^): NR; Anastrozole (*n*=101): Klinefelter's syndrome: NR, varicocele repair: 30 (29.7), varicocele present: 33 (32.6), overweight (BMI \>35 kg m^−2^): 16 (15.8)   Baseline, 3         2a
  Saylam *et al*.[@ref23] 2011, Turkey      Prospective, nonrandomized (single center)                                            Letrozole 2.5 mg daily                                  Total: 27                                                    34.92±6.66                              Idiopathic hypoandrogenic                                                                                                                                                                                                                                                                                              Baseline, 6         2a
  Gregoriou *et al*. 2012, Greece[@ref24]   Prospective, nonrandomized study (single center)                                      Letrozole 2.5 mg daily Anastrozole 1 mg daily           Total: 29 Letrozole (*n*=15) Anastrozole (*n*=14)            NR                                      Idiopathic hypoandrogenic                                                                                                                                                                                                                                                                                              Baseline, 6         2a
  Cavallini *et al*.[@ref20] 2013, Italy    Prospective, randomized, double-blind, placebo-controlled (multicentric)              Letrozole 2.5 mg daily Placebo                          Total: 45 Letrozole (*n*=22) Placebo (*n*=23)                44 (37--52) 45 (38--53)                 Idiopathic hypoandrogenic: 28 (62.2) Cryptorchidism: 17 (37.7)                                                                                                                                                                                                                                                         Baseline, 3, 6      1b
  Helo *et al*.[@ref26] 2015, USA           Prospective, randomized, double-blind (single center)                                 Clomiphene citrate 25 mg daily Anastrozole 1 mg daily   Total: 26 Clomiphene citrate (*n*=13) Anastrozole (*n*=13)   35±6.5 33±3.9                           Idiopathic hypoandrogenic                                                                                                                                                                                                                                                                                              Baseline, 3         1b
  Shoshany *et al*.[@ref25] 2017, USA       Retrospective survey^25^ (single center)                                              Anastrozole 1 mg daily                                  Total: 86                                                    37 (32--41)                             Idiopathic hypoandrogenic: 71 (82.5), cryptorchidism: 11 (12.7), varicocele repair: 4 (4.6)                                                                                                                                                                                                                            Baseline, 4         3

BMI: body mass index; LE: level of evidence; NR: not reported; s.d.: standard deviation

### Selection of the studies and criteria of inclusion {#sec3-2}

Entry into the analysis was restricted to data collected from original studies, including data from infertile couples (defined as failure to conceive for at least 12 months). Two authors (FDG and MLE) independently screened the titles and abstracts of all articles using predefined inclusion criteria. The full-text articles were examined independently by three authors (MLE, FDG, and EDB) to determine whether or not they met the inclusion criteria. Then, two authors (FDG and GMB) extracted data from the selected articles. Final inclusion was determined by consensus of all investigators.

All the female partners of the patients enrolled in the trials underwent basic diagnostic infertility evaluation and thus couples in whom female partners had a history of gynecologic surgery or ovulatory abnormalities were excluded from the analysis. The definition of hypogonadal oligo-azoospermia retrieved from the articles was based both on hormonal profiles (FSH concentrations within the normal range of reference values, low T levels \[\<400 ng dl^−1^\] and concomitant presence of a T/E~2~ ratio \<10) and on semen analyses (one or two below the normal references values according to the World Health Organization classification).[@ref15]

The presence of any of the following exclusion criteria potentially responsible for impaired semen values was noted: ejaculatory duct obstruction (obstructive azoospermia after testicular biopsy) or surgery for male factor infertility (*i.e*., ejaculatory tract obstruction); history of mumps orchitis, drugs, and tobacco or alcohol abuse; ongoing medical treatments including assumption of gonadotropins, anabolic steroids, exogenous T use, or other hormonal therapies; previous cancer radiochemotherapy; and positive seminal cultural analysis or positive urethral swab chlamydia test.

Therefore, we included in the analysis both idiopathic etiology and patients with known causes of testicular failure (*e.g*., Klinefelter\'s syndrome, Y chromosome microdeletion, varicocele untreated, and cryptorchidism) presenting with normo/oligo/crypto/azoospermic semen parameters and characterized by the presence of suppressed T/E~2~ ratio.

From each single clinical trial selected, the following data were extracted: treatment setting and regimens, total number of patients, presence/absence of randomization between active treatment/placebo, number of patients treated in each study arm, control arm including/not including placebo, cointerventions, hormonal and seminal outcomes stratified according to baseline and posttreatment mean values ± standard deviation (s.d.), standard mean difference (s.m.d.) and 95% confidence intervals (CIs), whether or not the trial noted a statistically significant difference in these outcomes between the compared arms, and side effects derived from AI administration (*P* \< 0.05 considered as statistically significant).

### Statistical analyses {#sec3-3}

To assess the risk of bias (RoB), all included reports were reviewed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for diagnostic accuracy studies.[@ref16] Of note, the "risk of bias" tool is designed for randomized controlled trials and should be used with caution on other types of studies. The two reviewing authors independently assessed the methodological quality based on sequence generation, allocation concealment, blinding of patients and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, ITT analysis, and additional sources of bias.

We compared treatments using s.m.d. and 95% CIs. Heterogeneity was evaluated by Chi-square Q test and I^2^ statistic.[@ref17] For the Q test, *P* \< 0.05 indicated significant heterogeneity; for the *I*^2^ statistics, an *I*^2^ value \>50% was considered significant. The pooled s.m.d. estimate was calculated using a random effects model.[@ref18] Our results are graphically displayed as forest plots, with s.m.d. indicating not better outcome in the experimental arm. Calculations were accomplished using the Comprehensive Meta-Analysis Software, version v.2.0 (CMA, Biostat, Englewood, NJ, USA).

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Search results {#sec3-4}

The database searches initially yielded 116 articles (PubMed: 87; Cochrane: 9; and Embase: 20). Seventy studies were excluded because they contained overlapping data or appeared in more than one database. Of these, 48 were subsequently removed due to duplication. On more detailed review, additional 33 papers were excluded for the following reasons: AIs with other topics (9), other drugs and/or breast cancer (12), animal experiment (5), and review paper or editorials (7). Full-text articles were then reevaluated and critically analyzed for the remaining 13 journal references. Of these, five did not meet the inclusion criteria. The remaining eight studies were considered for our systematic review (**[Figure 1](#F1){ref-type="fig"}** and **[Table 1](#T2){ref-type="table"}**). RoB assessment according to QUADAS-2 tool for each of the individual studies is illustrated in **Supplementary Figure 1**.

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.](AJA-22-360-g001){#F1}

### Study locations and types {#sec3-5}

Of the 8 studies entered in the review, 5 were conducted in the US, 2 in Europe, and 1 in Turkey. Two studies were prospective, randomized, double-blind, placebo-controlled studies,[@ref19][@ref20] with crossover between placebo and drug within the study of Clark and Sherins.[@ref19] The remaining five articles were divided into two prospective nonrandomized case--control studies,[@ref21][@ref22] two prospective nonrandomized single-arm trials,[@ref23][@ref24] and one retrospective survey.[@ref25] Moreover, two studies comparatively considered two different AIs (testolactone *vs* anastrozole and letrozole *vs* anastrozole) in the same study population,[@ref22][@ref24] while one study, designed as a prospective, randomized, double-blind study, compared an AI (Anastrozole) versus a selective estrogen receptor modulator (SERM -- Clomiphene Citrate).[@ref26]

### Study sample sizes, participant ages, and follow-up {#sec3-6}

The sample sizes varied from 25 to 140 cases analyzed in a single study. The total sample size of the eight studies was 517 patients. The total sample size of each individual treatment was 162 for testolactone, 214 for anastrozole, 64 for letrozole, and 48 for placebo. Three studies did not report participant\'s age.[@ref12][@ref19][@ref24] The range of mean age across the remaining five studies varied from 33 to 44 years. Age stratification for AIs implemented could not be performed due to available data and different statistical indices presented (mean *vs* median). In the studies, the follow-up after treatments ranged from 3 to 16 months (**[Table 1](#T2){ref-type="table"}**).

### Impact of AIs on serum testosterone and T/E~2~ ratio modification {#sec3-7}

The effect of AIs on testosterone level was considered in all eight studies. Seven out of eight articles evaluated T serum modification expressed as mean ± s.d. at the baseline and at the end of the scheduled follow-up. Only the analysis of Cavallini *et al*.[@ref20] reported the T levels as median (range) and was not included in the following analysis. From the remaining seven studies, there were 417 men treated with Als: the overall baseline T level was 320.1 ± 98.2 ng dl^−1^ whereas after treatment was 475.6 ± 60.3 ng dl^−1^ with a mean difference of 155.5 ng dl^−1^ (overall mean increase 48.5%). **[Supplementary Table 2a](#T3){ref-type="table"}** summarizes the overall hormonal serum modifications and stratified for single AIs identified among the studies analyzed.

###### 

\(a\) Overall and stratified mean hormonal modification and (b) overall and stratified mean semen parameters modification over the follow-up

  2a                                                     Overall mean modification       Stratification for single AIs                                                                                                                                                                             
  ------------------------------------------------------ ------------------------------- ----------------------------------- -------------- --------------------- ----------------- -------------- --------------------- ----------------- --------------- --------------------- ----------------- ---------------
  Testosterone (ng dl^−1^)                               320.1±98.2                      475.6±60.3                          155.5 (48.5)   401.2±117.1           479.5±85.4        78.2 (19.5)    266.5±20.2            454±43.5          187.5 (70.3)    265±14.1              511±22.6          246.2 (92.8)
  Clark and Sherins^19^, 1989, USA, (*n*=25)                                                                                                                                                                                                                                                       
  Pavlovich *et al*.[@ref21] 2001, USA, (*n*=63)                                                                                                                                                                                                                                                   
  Raman and Schlegel^22^ 2002, USA, (*n*=140)                                                                                                                                                                                                                                                      
  Saylam *et al*.[@ref23] 2011, Turkey, (*n*=27)                                                                                                                                                                                                                                                   
  Gregoriou *et al*.[@ref24] 2012, Greece, (*n*=29)                                                                                                                                                                                                                                                
  Helo *et al*.[@ref26] 2015, USA, (*n*=26)                                                                                                                                                                                                                                                        
  Shoshany *et al*.[@ref25] 2017, USA, (*n*=86)                                                                                                                                                                                                                                                    
  T/E2 ratio                                             7.4±1.6                         24.1±10.1                           16.7 (227.2)   5.1±0.2               12.5±0.2          7.4 (143.6)    7.9±1.2               23.3±7.7          15.3 (193.1)    8.5±0.7               37.5±2.1          29 (341.1)
  Pavlovich *et al*.[@ref21] 2001, USA, (*n*=63)                                                                                                                                                                                                                                                   
  Raman and Schlegel^22^, 2002, USA, (*n*=140)                                                                                                                                                                                                                                                     
  Saylam *et al*.[@ref23] 2011, Turkey, (*n*=27)                                                                                                                                                                                                                                                   
  Helo *et al*.[@ref26] 2015, USA, (*n*=26)                                                                                                                                                                                                                                                        
  Shoshany *et al*.[@ref25] 2017, USA, (*n*=86)                                                                                                                                                                                                                                                    
  Estradiol (pg ml^−1^)                                  36.9±13.7                       26.8±13.1                           −10 (−27.3)    47.3±17.1             39.9±14.4         −7.4 (−15.7)   34.4±10.6             23±5.8            −11.3 (−34.2)   26.3±0.5              14.7±0.2          −11.5 (−44.1)
  Clark and Sherins^19^ 1989, USA, (*n*=25)                                                                                                                                                                                                                                                        
  Pavlovich *et al*.[@ref21] 2001, USA, (*n*=63)                                                                                                                                                                                                                                                   
  Raman and Schlegel^22^ 2002, USA, (*n*=140)                                                                                                                                                                                                                                                      
  Saylam *et al*.[@ref23] 2011, Turkey, (*n*=27)                                                                                                                                                                                                                                                   
  Gregoriou *et al*.[@ref24] 2012, Greece, (*n*=29)                                                                                                                                                                                                                                                
  Helo *et al*.[@ref26] 2015, USA, (*n*=26)                                                                                                                                                                                                                                                        
  Shoshany *et al*.[@ref25] 2017, USA, (*n*=86)                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                   
  **2b**                                                 **Overall mean modification**   **Stratification for single AIs**                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                   
  **Testolactone (2 g/daily; 100--200 mg/daily)**        **Anastrozole (1 mg/daily)**    **Letrozole (2.5 mg/daily)**                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                   
  **Baseline**                                           **After treatment**             **Δ value (%)**                     **Baseline**   **After treatment**   **Δ value (%)**   **Baseline**   **After treatment**   **Δ value (%)**   **Baseline**    **After treatment**   **Δ value (%)**   
                                                                                                                                                                                                                                                                                                   
  Sperm concentration (×10^6^ ml^−1^)                    7.9±5.4                         17.2±8.1                            9.2 (116.3)    10.8±7.4              20.1±12.5         9.3 (86.1)     5.1±0.5               14.3±1.7          9.2 (181.3)     NE                    NE                NE
  Pavlovich *et al*.[@ref21] 2001, USA, (*n*=63)                                                                                                                                                                                                                                                   
  Raman and Schlegel^22^, 2002, USA, (*n*=140)                                                                                                                                                                                                                                                     
  Shoshany *et al*.[@ref25] 2017, USA, (*n*=86)                                                                                                                                                                                                                                                    
  Sperm motility (%)                                     18.6±12.4                       27.4±12.5                           8.7 (47)       20.8±8.7              33.1±17.1         12.2 (58.6)    29.7±15               32.7±9            3.1 (10.2)      9.1±2.8               17.5±6.4          8.5 (95.2)
  Pavlovich *et al*.[@ref21] 2001, USA, (*n*=63)                                                                                                                                                                                                                                                   
  Raman and Schlegel^22^, 2002, USA, (*n*=140)                                                                                                                                                                                                                                                     
  Saylam *et al*.[@ref23] 2010, Turkey, (*n*=27)                                                                                                                                                                                                                                                   
  Gregoriou *et al*.[@ref24] 2012, Greece, (*n*=29)                                                                                                                                                                                                                                                
  Shoshany *et al*.[@ref25] 2017, USA, (*n*=86)                                                                                                                                                                                                                                                    
  Total sperm count (×10^6^/ejaculated Vol.)             4.6±2.4                         7.9±2.3                             3.2 (69.8)     NE                    NE                NE             NE                    NE                NE              3.1±0.2               6.2±1.3           2.9 (92)
  Clark and Sherins[@ref19], 1989, USA, (*n*=25)                                                                                                                                                                                                                                                   
  Saylam *et al*.[@ref23] 2011, 2010, Turkey, (*n*=27)                                                                                                                                                                                                                                             
  Gregoriou *et al*.[@ref24] 2012, Greece, (*n*=29)                                                                                                                                                                                                                                                

NE: not evaluable

The study by Clark and Sherins[@ref19] using testolactone (*n* = 25) was the only experience demonstrating no difference in total T concentrations through the treatment period. In contrast, the double-blind, placebo-controlled study by Cavallini *et al*.[@ref20] (*n* = 45) reported a significant difference of 249 (range: 200.3--298.1) ng dl^−1^ versus 1198 (range: 768--1501) ng dl^−1^ at the baseline and after 6 months of letrozole administration (*P* \< 0.01). Moreover, this experience demonstrated a significant increase in T concentrations in the letrozole group (*n* = 22) when compared with the placebo-controlled group (*n* = 23) at the end of the follow-up (median: 1198 \[range: 768--1501\] ng dl^−1^ *vs* median: 266.2 \[range: 210.2--315.6\] ng dl^−1^).

Only five out of eight articles reported the effect of treatment on T/E~2~ ratio.[@ref21][@ref22][@ref23][@ref25][@ref26] Eight arms of treatment (*n* = 374) expressed T/E~2~ ratio values as mean ± s.d. at the baseline and at the end of scheduled follow-up. The baseline T/E~2~ ratio for the eight evaluated arms of treatment was 7.4 ± 1.6, and after AI treatment, T/E~2~ ratio was 24.1 ± 10.1, with a mean increase of 16.7 (overall mean increase 227%) (**[Supplementary Table 2a](#T3){ref-type="table"}**).

A meta-analysis was also performed to examine the effect of AIs on T levels in five eligible studies[@ref19][@ref23][@ref24][@ref25][@ref26] and T/E~2~ ratio in six eligible studies.[@ref21][@ref22][@ref23][@ref24][@ref25][@ref26] AI therapy significantly increased T levels from the baseline (s.m.d: 4.443, 95% CI: 1.634--7.253; *P* = 0.002, *I*^2^ = 97.85%; **Figure [2a](#F2){ref-type="fig"}** and **[2b](#F2){ref-type="fig"}**) and T/E~2~ ratio from the baseline (s.m.d: 8.006; 95% CI: 5.813--10.200; *P* \< 0.001 *I*^2^ = 95.8%; **[Figure 2c](#F2){ref-type="fig"}**).

![Standardized mean difference results for hormonal serum concentrations: (**a**) testosterone; (**b**) estradiol; and (**c**) T/E~2~ ratio, during aromatase inhibitor treatment for each study over follow-up. s.m.d: standardized mean difference; s.e.: standard error; CI: confidence interval: T: testosterone; E~2~: estradiol; df: degree of freedom.](AJA-22-360-g002){#F2}

### Impact of AIs on sperm concentration and sperm motility {#sec3-8}

Of the variables routinely evaluated in a semen analysis, the available data could be extrapolated only with regard to sperm concentration and sperm motility from those groups of patients presenting with oligo-, crypto-, and azoospermia at the baseline.

Three articles[@ref21][@ref22][@ref25] evaluated sperm concentration modification expressed as mean ± s.d. at the baseline and at the end of the scheduled follow-up. The analysis by Cavallini *et al*.[@ref20] reported this outcome as median (range) and was separately analyzed. The overall baseline total sperm concentration for the four evaluable arms of treatment was 7.9 ± 5.4 × 10[@ref6] ml^−1^ and after treatment was 17.2 ± 8.1 × 10[@ref6] ml^−1^, achieving a mean increase of 9.2 × 10[@ref6] ml^−1^ (overall mean increase 116.3%). Within these three articles[@ref21][@ref22][@ref25] examining azoospermia (*n* = 66), no sperm recovery from the ejaculated semen was found in the group of azoospermic patients at the end of follow-up.

Evaluation of the different AIs was specifically performed with regard to testolactone (*n* = 24) and anastrozole (*n* = 46) due to available data. **[Supplementary Table 2b](#T3){ref-type="table"}** summarizes the overall semen profile modifications and stratified for single AI implemented in the available trials. The study by Raman and Schlegel[@ref22] was the only experience to directly compare the two drugs and showed no significant differences in any sperm parameters and in particular sperm concentration (*P* = 0.47). Interesting findings in sperm concentration modification were reported by Cavallini *et al*.[@ref20] in their cohort of crypto-azoospermic patients. In the letrozole arm, a significant increase in sperm retrieval was recorded from the baseline to the end of treatment (median: 450 \[range: 0--900\] ml^−1^ *vs* median: 1.387 \[range: 632--1.904\] × 10[@ref6] ml^−1^; *P* \< 0.01). Moreover, this study reported a significant difference in sperm concentration when comparing patients treated with letrozole versus placebo (median: 1.387 \[range: 632--1.904\] × 10[@ref6] ml^−1^ *vs* median: 450 \[range: 0--900\] ml^−1^; *P* \< 0.01). In contrast to Raman and Schlegel, Pavlovich *et al*., and Shoshany *et al*. who did not report sperm in the ejaculate of AI-treated azoospermic men,[@ref21][@ref22][@ref25] the experience of Cavallini *et al*.[@ref20] showed some spermatozoa retrieval in the ejaculate of all the azoospermic patients (*n* = 6) after AI treatment (i.e., letrozole) in contrast to those in the placebo arm (*n* = 5) that remained azoospermic. In the study of Saylam *et al*.[@ref23] (Letrozole 2.5mg daily), 17 (62.9%) patients presented with azoospermia, 4 (23.5%) had spermatozoa retrived in their ejaculate after treatment with sperm count increased from 0 to (1.1 ± 0.69) × 10[@ref6] ml^−1^. However, this did not reach statistical significance (*P* = 0.125).

Of the five studies examining sperm motility,[@ref21][@ref22][@ref23][@ref24][@ref25] AI treatment demonstrated an increase from the baseline to the end of treatment. The overall baseline sperm motility was 18.6% ± 12.4%, whereas after treatment, it was 27.4% ± 12.5%, achieving a mean increase of 8.7% (overall mean increase of 47%). Among the studies that directly compared two AIs, Raman and Schlegel[@ref22] showed no significant difference between testolactone and anastrozole with regard to sperm motility (*P* = 0.63). Similarly, Gregoriou *et al*.[@ref24] reported a similar increase of 10.5% and 11% for anastrozole and letrozole, respectively (**[Supplementary Table 2b](#T3){ref-type="table"}**).

A meta-analysis was also performed to examine the effect of AIs on sperm concentration in three studies[@ref22][@ref23][@ref25] and sperm motility in five studies.[@ref21][@ref22][@ref23][@ref24][@ref25] AI therapy significantly increased sperm concentrations from the baseline (s.m.d: 2.595; 95% CI: 1.817--3.372; *P* \< 0.001, *I*^2^ = 65.1%; **Figure [3a](#F3){ref-type="fig"}** and **[3b](#F3){ref-type="fig"}**) and sperm motility (s.m.d: 2.291; 95% CI: 1.073--3.510; *P* \< 0.001, *I*^2^ = 93.3%; **[Figure 3c](#F3){ref-type="fig"}**).

![Standardized mean difference results for semen parameters: (**a**) sperm concentration; (**b**) total sperm count; and (**c**) sperm motility, during aromatase inhibitor treatment for each study over follow-up. s.m.d: standardized mean difference; s.e.: standard error; CI: confidence interval; df: degree of freedom.](AJA-22-360-g003){#F3}

### Drug tolerability and sides effects {#sec3-9}

We searched for the complications/side effects and reasons for discontinuing treatment reported within the different articles. All these variables are summarized in **[Table 2](#T4){ref-type="table"}**. The side effects reported were not life-threatening and resolved after the suspension of the therapy. In general, while AI treatment was overall well tolerated, various side effects were reported. Out of 436 patients on AI therapy, 14 (3.2%) discontinued the therapy due to the presence of side effects. Among the different adverse events, subclinical hepatic dysfunction, decrease/loss in libido, and drug intolerance were the most represented achieving a total number of events of 24 (5.5%), 11 (2.5%), and 10 (2.3%), respectively. All three drugs implemented were associated with episodes of subclinical hepatic dysfunction described both as asymptomatic liver function test increase and/or mild increases in transaminases and bilirubin values alone. Decrease or loss of libido was documented for anastrozole and letrozole administration. Studies also reported urticarial cutaneous rash as a reported side effect.[@ref19][@ref20][@ref26] Of note, no significant osteoarticular events or complications related to decreased bone density (rate of osteoporosis: 6.9% \[2/29\], Gregoriou *et al*.;[@ref24] 3.4% \[3/86\], Shoshany *et al*.;[@ref25] **[Table 2](#T4){ref-type="table"}**) were reported due to concerns of potential interference with bone metabolism. Moreover, no significant difference in terms of osteoporosis event rate was reported in the study of Gregoriou *et al*.[@ref24] when compared with the placebo group (letrozole: 6.9% *vs* placebo: 5.5%). However, the follow-up in these studies[@ref24][@ref25] was limited, which is consistent with the literature regarding long-term bone density effects in men.

###### 

Reported side effects from trials included

  Author, year, country                     Sample size (n)          Treatment enclosed               Drug intolerance, n (%)   Transient weakness, n (%)   Arthralgia and/or decreased bone density, n (%)   Nausea, n (%)   Headache, n (%)   Diarrhea, n (%)   Loss of hair, n (%)   Subclinical hepatic dysfunction, n (%)   Decrease/loss of libido, n (%)   Discontinuation due to side effects, n (%)
  ----------------------------------------- ------------------------ -------------------------------- ------------------------- --------------------------- ------------------------------------------------- --------------- ----------------- ----------------- --------------------- ---------------------------------------- -------------------------------- --------------------------------------------
  Clark and Sherins^19^1989, USA            25                       Testolactone 2 g daily           8 (32)                    NR                          NR                                                3 (12)          NR                NR                NR                    NR                                       NR                               2 (8)
  Pavlovich *et al*.[@ref21] 2001, USA      45                       Testolactone 100--200 mg daily   NR                        NR                          NR                                                NR              NR                NR                NR                    8 (17.7)                                 NR                               NR
  Raman and Schlegel^22^ 2002, USA          74                       Testolactone 100--200 mg daily   NR                        NR                          NR                                                NR              NR                NR                NR                    5 (6.9)                                  NR                               NR
  104                                       Anastrozole 1 mg daily                                    NR                        NR                          NR                                                NR              NR                NR                8 (7.4)               5 (4.8)                                  NR                               
  Saylam *et al*.[@ref23] 2011, Turkey      27                       Letrozole 2.5 mg daily           NR                        NR                          NR                                                NR              2 (7.4)           NR                NR                    NR                                       NR                               NR
  Gregoriou *et al*.[@ref24] 2012, Greece   15                       Letrozole 2.5 mg daily           NR                        1 (6.6)                     2 (6.9)                                           1 (6.6)         2 (13.3)          NR                NR                    1 (6.6)                                  NR                               NR
  14                                        Anastrozole 1 mg daily   NR                               NR                        NR                          2 (14.2)                                          1 (7.1)         1 (7.1)           NR                2 (14.2)              NR                                       NR                               
  Cavallini *et al*.[@ref20] 2013, Italy    22                       Letrozole 2.5 mg daily           2 (9)                     NR                          NR                                                NR              NR                NR                1 (4.5)               NR                                       5 (22.7)                         4 (18.1)
  23                                        Placebo                  NR                               NR                        NR                          NR                                                NR              NR                NR                NR                    NR                                       NR                               
  Helo *et al*.[@ref26] 2015, USA           24                       Anastrozole 1 mg daily           NR                        NR                          NR                                                NR              NR                NR                NR                    NR                                       NR                               NR
  Shoshany *et al*.[@ref25] 2017, USA       86                       Anastrozole 1 mg daily           NR                        NR                          3 (3.4)                                           NR              NR                NR                NR                    NR                                       1 (1.1)                          8 (9.3)
  Total                                     436                                                       10 (2.3)                  1 (0.3)                     5 (1.1)                                           6 (1.4)         5 (1.1)           1 (0.3)           1 (0.3)               24 (5.5)                                 11 (2.5)                         14 (3.2)

NR: not reported

DISCUSSION {#sec1-4}
==========

The purpose of our analysis was to evaluate the state of evidence regarding the use of AIs for men with testicular dysfunction. Despite heterogeneity in the literature with respect to patient characteristics, study design, and measured outcomes, a systematic review and meta-analysis was carried out for multiple hormonal and semen variables.

The trend of T serum modification over the follow-up represented the main outcome analyzed among the studies included in the review. Overall, all the studies reported a significant increase in serum T after AI administration (overall mean increase 48.5%; LE:1b). Only two studies[@ref22][@ref24] using two different AIs on the same cohort population were identified. In particular, no difference in improvement of T concentrations between individual AIs was noted. For example, in the study of Raman and Schlegel,[@ref22] no difference between steroidal (testolactone) and nonsteroidal AIs (anastrozole) could be assessed. Moreover, we were not able to compare the two available randomized placebo-controlled trials[@ref19][@ref20] included in the review due to different study designs (randomized placebo-controlled with crossover *vs* randomized placebo-controlled), different drugs administered, and different statistical indices presented in the results section (mean ± s.d. *vs* median \[range\]). Of these, the study by Clark and Sherins[@ref19] (testolactone) was the only one reporting no significant differences in total T concentrations over treatment, whereas the study by Cavallini *et al*.[@ref20] (letrozole) demonstrated a significant improvement of serum T concentrations in the nonsteroidal AI treatment group compared to placebo administration (LE:1b). While an overall serum T improvement was demonstrated (s.m.d: 4.443, 95% CI: 1.634--7.253; *P* = 0.002, *I*^2^ = 97.85%; **Figure [2a](#F2){ref-type="fig"}** and **[2b](#F2){ref-type="fig"}**), we could not conclude that there were significant differences in efficacy between the multiple AIs due to lack of available data.

AI therapy significantly increased T/E~2~ ratios (overall mean increase 227%; LE:2a). In the present review, the study by Ramanand Schlegel[@ref22] reported improvements in the T/E~2~ ratio. Of note, both randomized placebo-controlled trials[@ref19][@ref20] enrolled in the present review did not report numeric information regarding the T/E~2~ levels modification.

The rationale behind the use of AIs as a potential tool to restore hormonal impairment and thus to treat idiopathic hypogonadal infertile males resides on the fact that more than 50% of circulating E~2~ is derived from peripheral aromatization of androgens.[@ref27][@ref28] Moreover, T and E~2~ together with Sertoli cell-produced inhibin have found to be independently regulated, but strictly connected with the negative feedback modulating the release of pituitary gonadotropins. High E~2~ levels together with low circulating T exert a negative feedback on the HPA by suppressing the FSH and LH production and thus negatively regulating spermatogenesis.[@ref29][@ref30][@ref31] More recently, a rat model developed by Dumasia *et al*.[@ref32] demonstrated how exposure to agonist E~2~ administration may directly impact germinal epithelium by inducing germ cell apoptosis and spermiation failure by separate regulation of E~2~ receptors. AI administration in patients with impaired T/E~2~ ratio will decrease peripheral T to E~2~ conversion inducing a hypoestrogenic state which releases the HPA from the negative E~2~ effect and thus improving the hormonal profile and semen parameters.[@ref33][@ref34]

Certain limitations warrant mention. While we attempt for high scientific rigor, we are bound the existing literature which includes relatively few studies. As such, we performed a systematic review and meta-analysis only comparing available data (randomized clinical trials and prospective longitudinal and retrospective studies; **[Table 1](#T2){ref-type="table"}**) with limited ability to compare active treatments versus placebo administration. While data regarding hormonal parameters clearly improve among all the trials enrolled over the follow-up demonstrating some degree of consistency across the studies, the adoption of different seminal variables (*i.e*., sperm concentration or total sperm count) reduces the sample size of the evaluable population, therefore impacting on potency of the outcomes retrieved. In conclusion, we also recognize that pregnancy outcomes are not available in these studies, which limits the assessment of fertility outcomes.

Although AIs are FDA approved for the treatment of early and late-stage breast cancer, their use for male infertility is limited to off-label implementation. In our meta-analysis, the use of AIs in patients suffering from idiopathic or known causes of testicular failure resulted in a marked increase in serum T concentrations and T/E~2~ ratio. Moreover, a similar positive effect on semen profiles of these patients was identified, albeit in a limited number of studies. In addition, only one of four studies (Cavallini *et al*.[@ref20]) demonstrated the efficacy of AI therapy in yielding sperm in the ejaculate of azoospermic men. Moreover, as previously observed by Schlegel,[@ref12] improvement in semen profiles appears to be more commonly achieved when selection criteria of the studies are based on lower baseline parameters. Thus, regression to the mean may result in higher values after treatment. In this setting, without future strict inclusion criteria regarding sperm concentration status, it could be difficult to identify a particular subset of patients who could expect a better prognosis from AI therapy. Moreover, lack of substantial amount of available data on patients suffering from other male factor diagnoses such as Klinefelter\'s syndrome and varicoceles precludes the possibility to further discuss AI use in this setting. Raman and Schlegel have demonstrated how anastrozole implementation could potentially be less efficacious in semen outcome improvement among men with Klinefelter\'s syndrome due to probable drug mechanism of action inability to inhibit adrenal steroidal synthesis. At the same time, in the subset of obese subfertile patients, the authors have also demonstrated how AI therapy did not show greater benefit than the rest of the population.[@ref22] With the present evidence, we were not able to establish any conclusions on such restricted category of patients. AI therapy before sperm retrieval could be a promising neoadjuvant option to increase the chances of sperm detection. Further prospective randomized studies focused on such selected category of infertile patients are therefore necessary before implementing AI in clinical practice.

CONCLUSION {#sec1-5}
==========

Currently, the number and quality of the studies focusing on AIs for male testicular dysfunction remain low. Nevertheless, our systematic review and meta-analysis suggests the ability of AIs to improve hormone and semen profiles in a safe, well-tolerated manner. However, future randomized multicenter trials are necessary to better define the efficacy and risks of these medications in the clinical management of infertile men.

AUTHORS CONTRIBUTIONS {#sec1-6}
=====================

FDG, MLE, GMB and EDB take responsibility for the integrity of the data and accuracy of the data analysis while study concept and design of the study was developed by MLE, FDG, and MSG. All authors contributed to acquisition, analysis, and/or interpretation of data. Drafting of the manuscript was performed by FDG, AS, GMB, and MLE. Statistical analysis has been performed by MM, IS, and MF. MLE and GMB has been the study supervisor of the entire project. All authors read and approved the final manuscript.

COMPETING INTERESTS {#sec1-7}
===================

All authors declared no competing interests.

Supplementary Information in linked to the online version of the paper on *Asian Journal of Andrology* website.

###### 

Risk of bias assessment according to QUADAS-2. RoB: risk of bias; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies.
